Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) Stock Price

KNSAStock
$80.20+135.20%52W
Market Cap$6.26B
P/E102.92x
PEG Ratio
Div yield
Beta0.03

KNSA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)63.64%
Price vs S&P 500 (4W)-3.13%
VGM Score63.25
P/E Ratio (Annual)102.92x

KNSA Earnings Surprise History

Q2 250.23est. 0.26
Q3 250.23est. 0.37
Q4 250.17est. 0.40
Q1 260.27est. 0.16
Q2 260.30est. 0.28

KNSA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.29
4.29
4.29
4.29

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares
DAA$80.20
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares

Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for cardiovascular diseases. Its pipeline includes three lead candidates: Rilonacept, abiprubart, and Vixarelimab, with primary operations in the United States.